Stoke Therapeutics (STOK) Change in Receivables (2024 - 2026)

Stoke Therapeutics' Change in Receivables history runs 3 years deep, the most recent figure standing at -$1.5 million for Q1 2026.

• On a quarterly basis, Change in Receivables fell 212.15% year-over-year to -$1.5 million in Q1 2026; TTM through Mar 2026 was -$3.8 million, a N/A change from a year earlier, with the FY2025 full-year figure at $4.3 million, up 8436.0% from the prior year.
• Change in Receivables improved to -$1.5 million in Q1 2026 per STOK's latest filing, from -$3.3 million in the prior quarter.
• Across five years, Change in Receivables topped out at $1.3 million in Q1 2025 and bottomed at -$3.3 million in Q4 2025.
• The 3-year median for Change in Receivables is -$892000.0 (2024), against an average of -$942750.0.
• Across the five-year window, Change in Receivables tumbled 1011.41% in 2025 and tumbled 212.15% in 2026, its largest moves.
• Year by year, Change in Receivables stood at -$298000.0 in 2024, then tumbled by 1011.41% to -$3.3 million in 2025, then surged by 55.13% to -$1.5 million in 2026.
• Per Business Quant, the three latest STOK Change in Receivables figures stand at -$1.5 million (Q1 2026), -$3.3 million (Q4 2025), and $1.3 million (Q1 2025).